

Pietro Invernizzi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8742349/pietro-invernizzi-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

353
papers

18,462
citations

68
h-index

125
g-index

419
ext. papers

23,035
ext. citations

7.4
avg. IF

6.81
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------------|
| 353 | Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules.. <i>Nature Immunology</i> , 2022 , | 19.1 | 14 |
| 352 | Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance.. <i>World Journal of Gastroenterology</i> , 2022 , 28, 1123-1138 | 5.6 | 0 |
| 351 | Hepatitis C virus infection and diabetes: a complex bidirectional relationship.. <i>Diabetes Research and Clinical Practice</i> , 2022 , 109870 | 7.4 | |
| 350 | Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. <i>Immunotherapy</i> , 2021 , | 3.8 | 1 |
| 349 | Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1138-1146 | 6.1 | 8 |
| 348 | MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 Severity. <i>Journal of Personalized Medicine</i> , 2021 , 11, | 3.6 | 1 |
| 347 | The mode of dexamethasone decoration influences Avidin-nucleic-acid-Nano-assembly organ biodistribution and in vivo drug persistence. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021 , 102497 | 6 | 0 |
| 346 | Effects of Immunosuppressive Drugs on COVID-19 severity in Patients with Autoimmune Hepatitis. <i>Liver International</i> , 2021 , | 7.9 | 3 |
| 345 | E. coli and the Etiology of Human PBC: Anti-mitochondrial Antibodies and Spreading Determinants. <i>Hepatology</i> , 2021 , | 11.2 | 1 |
| 344 | Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study. <i>Endocrine</i> , 2021 , 75, 942 | 4 | 1 |
| 343 | Acute carnosine and Alanine supplementation increase the compensated part of the ventilation versus work rate relationship during a ramp incremental cycle test in physically active men. <i>Journal of Sports Medicine and Physical Fitness</i> , 2021 , 61, 37-43 | 1.4 | 0 |
| 342 | Cost of illness of Primary Biliary Cholangitis - a population-based study. <i>Digestive and Liver Disease</i> , 2021 , 53, 1167-1170 | 3.3 | 0 |
| 341 | Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1688-1697 | 6.9 | 14 ⁵ |
| 340 | Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 2227-2234 | 5.2 | 3 |
| 339 | Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 6 |
| 338 | Old and novel prognostic biomarkers in primary biliary cholangitis. <i>Expert Opinion on Orphan Drugs</i> , 2021 , 9, 123-131 | 1.1 | |
| 337 | Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis. <i>Frontiers in Immunology</i> , 2021 , 12, 673487 | 8.4 | 1 |

| | | | |
|-----|--|------|----|
| 336 | Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021 , 3, 100248 | 10.3 | 10 |
| 335 | Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021 , 53, 1603-1609 | 3.3 | |
| 334 | Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. <i>Hepatology</i> , 2021 , 74, 1496-1508 | 11.2 | 4 |
| 333 | Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. <i>Hepatology</i> , 2021 , 73, 2099-2109 | 11.2 | 18 |
| 332 | X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021 , 160, 2483-2495.e26 | 13.3 | 9 |
| 331 | Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021 , 53, 367-374 | 3.3 | 3 |
| 330 | Reply to: "A spotlight on natural killer cells in primary biliary cholangitis". <i>Journal of Hepatology</i> , 2021 , 74, 255-256 | 13.4 | |
| 329 | DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma. <i>Hepatology</i> , 2021 , 73, 144-159 | 11.2 | 10 |
| 328 | Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease?. <i>Journal of Translational Autoimmunity</i> , 2021 , 4, 100124 | 4.1 | |
| 327 | Elastography in Autoimmune Liver Diseases 2021 , 91-103 | | |
| 326 | The seat of life. What a lesson from the stigmatized saints. <i>Liver International</i> , 2021 , 41, 1675-1676 | 7.9 | 1 |
| 325 | Acute mesenteric ischemia and small bowel imaging findings in COVID-19: A comprehensive review of the literature. <i>World Journal of Gastrointestinal Surgery</i> , 2021 , 13, 702-716 | 2.4 | 6 |
| 324 | An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021 , 75, 572-581 | 13.4 | 8 |
| 323 | The genetic architecture of primary biliary cholangitis. <i>European Journal of Medical Genetics</i> , 2021 , 64, 104292 | 2.6 | 5 |
| 322 | Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. <i>World Journal of Gastroenterology</i> , 2021 , 27, 5890-5907 | 5.6 | 4 |
| 321 | The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma. <i>Liver International</i> , 2021 , | 7.9 | 1 |
| 320 | Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. <i>Clinical and Translational Science</i> , 2021 , | 4.9 | 6 |
| 319 | Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. <i>World Journal of Gastroenterology</i> , 2021 , 27, 5520-5535 | 5.6 | 1 |

| | | | |
|-----|---|------|-----|
| 318 | Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. <i>Journal of Translational Autoimmunity</i> , 2021 , 4, 100081 | 4.1 | 1 |
| 317 | Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17, | 4.6 | 5 |
| 316 | Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2375-2377 | 6.9 | 19 |
| 315 | Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. <i>Diseases (Basel, Switzerland)</i> , 2020 , 8, | 4.4 | 4 |
| 314 | Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1522-1534 | 59.2 | 913 |
| 313 | Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. <i>Journal of Autoimmunity</i> , 2020 , 113, 102503 | 15.5 | 4 |
| 312 | High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020 , 73, 1063-1071 | 13.4 | 158 |
| 311 | Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. <i>Liver International</i> , 2020 , 40, 1121-1129 | 7.9 | 6 |
| 310 | Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. <i>Cells</i> , 2020 , 9, | 7.9 | 3 |
| 309 | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. <i>Cells</i> , 2020 , 9, | 7.9 | 24 |
| 308 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 557-588 | 24.2 | 355 |
| 307 | Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1066-1074 | 0.7 | 31 |
| 306 | Comment on "Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis". <i>Disease Markers</i> , 2020 , 2020, 2453908 | 3.2 | 1 |
| 305 | Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis. <i>Journal of Leukocyte Biology</i> , 2020 , 108, 659-671 | 6.5 | 7 |
| 304 | Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. <i>Liver International</i> , 2020 , 40, 1408-1414 | 7.9 | 13 |
| 303 | New Therapeutic Targets in Autoimmune Cholangiopathies. <i>Frontiers in Medicine</i> , 2020 , 7, 117 | 4.9 | 12 |
| 302 | Genetics of Autoimmune Liver Diseases 2020 , 69-85 | | 0 |
| 301 | Combined ursodeoxycholic acid/secretin treatment reduces biliary senescence and liver fibrosis in a murine model of late stage primary biliary cholangitis. <i>FASEB Journal</i> , 2020 , 34, 1-1 | 0.9 | |

| | | | |
|-----|--|------|----|
| 300 | Open challenges in the management of autoimmune hepatitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2020 , | 1.6 | 1 |
| 299 | Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 33, | 2.2 | 1 |
| 298 | Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. <i>Annals of Hepatology</i> , 2020 , 19, 5-16 | 3.1 | 8 |
| 297 | Understanding short bowel syndrome: Current status and future perspectives. <i>Digestive and Liver Disease</i> , 2020 , 52, 253-261 | 3.3 | 24 |
| 296 | Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?. <i>Hepatology</i> , 2020 , 72, 359-360 | 11.2 | 1 |
| 295 | Individualizing Care: Management Beyond Medical Therapy. <i>Surgical Oncology Clinics of North America</i> , 2020 , 29, 87-103 | 2.7 | |
| 294 | Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28137 | 3 | 6 |
| 293 | Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <i>Digestive and Liver Disease</i> , 2020 , 52, 190-198 | 3.3 | 6 |
| 292 | Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2020 , 8, 140-147 | 5.3 | 8 |
| 291 | Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020 , 35, 141-148 | 2.5 | 6 |
| 290 | Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets. <i>Journal of Hepatology</i> , 2020 , 73, 965-966 | 13.4 | 7 |
| 289 | 2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102618 | 13.6 | 36 |
| 288 | Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. <i>Hepatology Communications</i> , 2020 , 4, 1257 | 6 | 33 |
| 287 | Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. <i>Liver International</i> , 2020 , 40, 2590-2601 | 7.9 | 5 |
| 286 | COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e138-e139 | 4.5 | 1 |
| 285 | Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) \geq cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020 , 7, 598438 | 4.9 | 7 |
| 284 | Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 684-692.e6 | 6.9 | 10 |
| 283 | Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis. <i>Hepatology</i> , 2020 , 71, 990-1008 | 11.2 | 18 |

| | | | |
|-----|---|------|-----|
| 282 | Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515 | 13.4 | 113 |
| 281 | Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020 , 69, 1502-1509 | 19.2 | 13 |
| 280 | Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , 2020 , 73, 453-455 | 13.4 | 40 |
| 279 | The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , 2019 , 105, 102328 | 15.5 | 45 |
| 278 | Knockout of Calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes. <i>Laboratory Investigation</i> , 2019 , 99, 764-776 | 5.9 | 10 |
| 277 | Multi-Teaching Styles Approach and Active Reflection: Effectiveness in Improving Fitness Level, Motor Competence, Enjoyment, Amount of Physical Activity, and Effects on the Perception of Physical Education Lessons in Primary School Children. <i>Sustainability</i> , 2019 , 11, 405 | 3.6 | 25 |
| 276 | GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. <i>Journal of Hepatology</i> , 2019 , 70, e1-e2 | 13.4 | 10 |
| 275 | Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency. <i>Journal of Digestive Diseases</i> , 2019 , 20, 363-370 | 3.3 | 3 |
| 274 | Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 483-494 | 4.4 | 15 |
| 273 | Precision medicine in primary biliary cholangitis. <i>Journal of Digestive Diseases</i> , 2019 , 20, 338-345 | 3.3 | 5 |
| 272 | CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 2246-2256 | 6.9 | 7 |
| 271 | Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. <i>Liver International</i> , 2019 , 39, 2124-2135 | 7.9 | 2 |
| 270 | Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 1525-1539 | 6.9 | 11 |
| 269 | Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model. <i>ACS Nano</i> , 2019 , 13, 4410-4423 | 16.7 | 24 |
| 268 | Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2076-2084.e2 | 6.9 | 27 |
| 267 | Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. <i>Liver International</i> , 2019 , 39 Suppl 1, 79-97 | 7.9 | 16 |
| 266 | Iron Metabolism in Liver Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2019 , 9, 149 | 5.3 | 7 |
| 265 | Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019 , 71, 357-365 | 13.4 | 80 |

| | | | |
|-----|--|------|-----|
| 264 | Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA. <i>Hepatology</i> , 2019 , 69, 2562-2578 | 11.2 | 19 |
| 263 | FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019 , 70, e390-e391 | 13.4 | 2 |
| 262 | Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. <i>Journal of Hepatology</i> , 2019 , 71, 1216-1228 | 13.4 | 163 |
| 261 | A National Hospital-Based Study of Hospitalized Patients With Primary Biliary Cholangitis. <i>Hepatology Communications</i> , 2019 , 3, 1250-1257 | 6 | 6 |
| 260 | Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. <i>American Journal of Pathology</i> , 2019 , 189, 2090-2101 | 5.8 | 14 |
| 259 | Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. <i>FASEB Journal</i> , 2019 , 33, 10269-10279 | 0.9 | 18 |
| 258 | Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1127-1136 | 6.1 | 29 |
| 257 | Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2 mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019 , 1865, 165557 | 6.9 | 13 |
| 256 | Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2019 , 10, 3931-3938 | 3.3 | 3 |
| 255 | Better end points needed in primary sclerosing cholangitis trials. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 143-144 | 24.2 | 5 |
| 254 | The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. <i>Autoimmunity Reviews</i> , 2019 , 18, 215-222 | 13.6 | 47 |
| 253 | Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. <i>Digestive and Liver Disease</i> , 2018 , 50, 698-702 | 3.3 | 15 |
| 252 | Comprehensive review of autoantibodies in patients with hyper-IgM syndrome. <i>Cellular and Molecular Immunology</i> , 2018 , 15, 610-617 | 15.4 | 4 |
| 251 | Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 54, 295-306 | 12.3 | 11 |
| 250 | NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. <i>Hepatology Communications</i> , 2018 , 2, 492-503 | 6 | 24 |
| 249 | Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2 mice and human cholangiocarcinoma tumorigenesis. <i>Hepatology</i> , 2018 , 68, 1042-1056 | 11.2 | 32 |
| 248 | Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy. <i>Digestive and Liver Disease</i> , 2018 , 50, 21-22 | 3.3 | 2 |
| 247 | The Epigenetics of Primary Biliary Cholangitis 2018 , 251-272 | | |

| | | | |
|-----|--|------|----|
| 246 | Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers. <i>Autoimmunity Reviews</i> , 2018 , 17, 854-865 | 13.6 | 18 |
| 245 | Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 626-634 | 18.8 | 60 |
| 244 | Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2 mice and human primary sclerosing cholangitis. <i>Laboratory Investigation</i> , 2018 , 98, 1465-1477 | 5.9 | 20 |
| 243 | Study of the influence of heme oxygenase 1 gene single nucleotide polymorphism (rs2071746) on esophageal varices among patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 888-892 | 2.2 | 5 |
| 242 | Dermatological Complications After Solid Organ Transplantation. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 54, 185-212 | 12.3 | 29 |
| 241 | Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018 , 113, 254-264 | 0.7 | 44 |
| 240 | Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018 , 67, 1920-1930 | 11.2 | 35 |
| 239 | A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation. <i>Hepatology</i> , 2018 , 67, 232-246 | 11.2 | 21 |
| 238 | Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018 , 67, 1517-1524 | 19.2 | 28 |
| 237 | Prognostic models in primary biliary cholangitis. <i>Journal of Autoimmunity</i> , 2018 , 95, 171-178 | 15.5 | 14 |
| 236 | "I Miss My Liver." Nonmedical Sources in the History of Hepatocentrism. <i>Hepatology Communications</i> , 2018 , 2, 982-989 | 6 | 6 |
| 235 | The immunobiology of female predominance in primary biliary cholangitis. <i>Journal of Autoimmunity</i> , 2018 , 95, 124-132 | 15.5 | 14 |
| 234 | Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis Even in patients without biochemical improvements. <i>Journal of Hepatology</i> , 2018 , 68, S8 | 13.4 | 5 |
| 233 | Geoepidemiology and (epi-)genetics in primary biliary cholangitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2018 , 34-35, 11-15 | 2.5 | 6 |
| 232 | Individualizing Care: Management Beyond Medical Therapy. <i>Clinics in Liver Disease</i> , 2018 , 22, 545-561 | 4.6 | 3 |
| 231 | The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. <i>Hepatology</i> , 2017 , 65, 1670-1682 | 11.2 | 26 |
| 230 | miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. <i>American Journal of Pathology</i> , 2017 , 187, 570-580 | 5.8 | 21 |
| 229 | Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017 , 65, 299-309 | 4 | 9 |

| | | | |
|-----|--|------|-----|
| 228 | Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <i>Liver International</i> , 2017 , 37, 1554-1561 | 7.9 | 39 |
| 227 | Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017 , 152, 1975-1984.e8 | 13.3 | 219 |
| 226 | Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. <i>Hepatology</i> , 2017 , 66, 528-541 | 11.2 | 51 |
| 225 | EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2017 , 67, 145-172 | 13.4 | 512 |
| 224 | Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. <i>American Journal of Pathology</i> , 2017 , 187, 1551-1565 | 5.8 | 12 |
| 223 | Primary Biliary Cholangitis: advances in management and treatment of the disease. <i>Digestive and Liver Disease</i> , 2017 , 49, 841-846 | 3.3 | 15 |
| 222 | Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. <i>Cancer Letters</i> , 2017 , 386, 179-188 | 9.9 | 26 |
| 221 | Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation. <i>FASEB Journal</i> , 2017 , 31, 4305-4324 | 0.9 | 35 |
| 220 | Treatment of PBC-A step forward. <i>Liver International</i> , 2017 , 37, 503-505 | 7.9 | 4 |
| 219 | Human δ Defensin 2 in Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e80 | 4.2 | 3 |
| 218 | Nicotine Promotes Cholangiocarcinoma Growth in Xenograft Mice. <i>American Journal of Pathology</i> , 2017 , 187, 1093-1105 | 5.8 | 13 |
| 217 | Expert clinical management of autoimmune hepatitis in the real world. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 723-732 | 6.1 | 48 |
| 216 | Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017 , 49, 269-273 | 36.3 | 140 |
| 215 | Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 53, 394-412 | 12.3 | 19 |
| 214 | From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 1121-1131 | 5.1 | 10 |
| 213 | Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. <i>Scientific Reports</i> , 2017 , 7, 17667 | 7.9 | 39 |
| 212 | Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2 mice. <i>Journal of Surgical Research</i> , 2017 , 217, 160-169 | 2.5 | 13 |
| 211 | Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice. <i>Hepatology</i> , 2017 , 65, 544-559 | 11.2 | 33 |

| | | | |
|-----|--|------|-----|
| 210 | Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. <i>Journal of Hepatology</i> , 2017 , 66, 102-115 | 13.4 | 91 |
| 209 | Cytokines in the Liver: Cytokine Mechanisms in Liver Health and Disease 2017 , 75-96 | | 0 |
| 208 | Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. <i>Oncogene</i> , 2016 , 35, 671-82 | 9.2 | 95 |
| 207 | A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016 , 375, 631-43 | 59.2 | 574 |
| 206 | Effects of Acute Carnosine and Alanine on Isometric Force and Jumping Performance. <i>International Journal of Sports Physiology and Performance</i> , 2016 , 11, 344-9 | 3.5 | 3 |
| 205 | Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice. <i>Hepatology</i> , 2016 , 64, 1202-1216 | 11.2 | 51 |
| 204 | Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. <i>Laboratory Investigation</i> , 2016 , 96, 1256-1267 | 5.9 | 35 |
| 203 | Novel treatments targeting immune-related mechanisms in primary biliary cholangitis. <i>Clinical Liver Disease</i> , 2016 , 8, 127-131 | 2.2 | 1 |
| 202 | Identification of Circulating MicroRNAs in Biliary Atresia by Next-Generation Sequencing. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016 , 63, 518-523 | 2.8 | 15 |
| 201 | Toward precision medicine in primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2016 , 48, 843-50 | 3.3 | 9 |
| 200 | Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016 , 65, 321-9 | 19.2 | 107 |
| 199 | Elevated circulating CD14CD16 monocyte subset in primary biliary cirrhosis correlates with liver injury and promotes Th1 polarization. <i>Clinical and Experimental Medicine</i> , 2016 , 16, 511-521 | 4.9 | 12 |
| 198 | Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. <i>Gut</i> , 2016 , 65, 1998-2006 | 19.2 | 35 |
| 197 | AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , 2016 , 48, 120-37 | 3.3 | 23 |
| 196 | Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. <i>Autoimmunity Reviews</i> , 2016 , 15, 162-6 | 13.6 | 34 |
| 195 | Making Sense of Autoantibodies in Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , 2016 , 20, 33-46 | 4.6 | 17 |
| 194 | Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. <i>Journal of Autoimmunity</i> , 2016 , 66, 40-50 | 15.5 | 152 |
| 193 | Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. <i>PLoS ONE</i> , 2016 , 11, e0159612 | 3.7 | 19 |

| | | | |
|-----|--|------|-----|
| 192 | Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach. <i>Autoimmunity Reviews</i> , 2016 , 15, 870-6 | 13.6 | 30 |
| 191 | The epigenetics of PBC: The link between genetic susceptibility and environment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 650-659 | 2.4 | 22 |
| 190 | The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor- β biliary secretion in mice. <i>Hepatology</i> , 2016 , 64, 865-79 | 11.2 | 56 |
| 189 | Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Clinical and Experimental Immunology</i> , 2016 , 185, 61-71 | 6.2 | 59 |
| 188 | Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. <i>Scientific Reports</i> , 2016 , 6, 25906 | 4.9 | 82 |
| 187 | Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 261-80 | 24.2 | 618 |
| 186 | Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. <i>Journal of Hepatology</i> , 2015 , 62, 198-207 | 13.4 | 57 |
| 185 | Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. <i>Immunobiology</i> , 2015 , 220, 1025-9 | 3.4 | 15 |
| 184 | The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2015 , 47, 432-5 | 3.3 | 21 |
| 183 | Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>American Journal of Gastroenterology</i> , 2015 , 110, 1536-8 | 0.7 | 26 |
| 182 | Changing nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Digestive and Liver Disease</i> , 2015 , 47, 924-6 | 3.3 | 14 |
| 181 | Changing nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Gastroenterology</i> , 2015 , 149, 1627-9 | 13.3 | 56 |
| 180 | Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1867-9 | 6.9 | 14 |
| 179 | International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , 2015 , 6, 8019 | 17.4 | 185 |
| 178 | Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015 , 149, 1804-1812.e4 | 13.3 | 235 |
| 177 | Changing nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Journal of Hepatology</i> , 2015 , 63, 1285-7 | 13.4 | 55 |
| 176 | INTERPRETATION AND PERCEPTION OF TWO DIFFERENT KUMITE FIGHTING INTENSITIES THROUGH AN INTEGRATED APPROACH TRAINING IN INTERNATIONAL LEVEL KARATEKAS: AN EXPLORATORY STUDY. <i>Perceptual and Motor Skills</i> , 2015 , 121, 333-49 | 2.2 | 5 |
| 175 | DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. <i>Clinical Epigenetics</i> , 2015 , 7, 61 | 7.7 | 66 |

| | | | |
|-----|--|------|-----|
| 174 | Changing nomenclature for PBC: From PcirrhosisPto PcholangitisP. <i>Gut</i> , 2015 , 64, 1671-2 | 19.2 | 22 |
| 173 | Autonomic modulations of heart rate variability and performances in short-distance elite swimmers. <i>European Journal of Applied Physiology</i> , 2015 , 115, 825-35 | 3.4 | 12 |
| 172 | Changing nomenclature for PBC: From PcirrhosisPto PcholangitisP. <i>Hepatology</i> , 2015 , 62, 1620-2 | 11.2 | 92 |
| 171 | Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. <i>Mediators of Inflammation</i> , 2015 , 2015, 436450 | 4.3 | 20 |
| 170 | Changing nomenclature for PBC: From PcirrhosisPto PcholangitisP. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, e57-9 | 2.4 | 29 |
| 169 | Geoepidemiology, Genetic and Environmental Risk Factors for PBC. <i>Digestive Diseases</i> , 2015 , 33 Suppl 2, 94-101 | 3.2 | 24 |
| 168 | Advances in pharmacotherapy for primary biliary cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 633-43 | 4 | 25 |
| 167 | Infection and Autoimmune Liver Diseases 2015 , 839-857 | | |
| 166 | The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. <i>Genes and Immunity</i> , 2015 , 16, 193-8 | 4.4 | 12 |
| 165 | Gene dosage as a relevant mechanism contributing to the determination of ovarian function in Turner syndrome. <i>Human Reproduction</i> , 2014 , 29, 368-79 | 5.7 | 33 |
| 164 | Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2014 , 46, 363-8 | 3.3 | 11 |
| 163 | Macrophage plasticity and polarization in liver homeostasis and pathology. <i>Hepatology</i> , 2014 , 59, 2034-42 | 11.2 | 274 |
| 162 | Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. <i>European Journal of Immunology</i> , 2014 , 44, 945-54 | 6.1 | 26 |
| 161 | Smooth Muscle Autoantibodies 2014 , 491-495 | | |
| 160 | Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. <i>Hepatology</i> , 2014 , 60, 1314-23 | 11.2 | 64 |
| 159 | Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and microRNA let7a in mice. <i>Gastroenterology</i> , 2014 , 146, 1795-808.e12 | 13.3 | 67 |
| 158 | The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury. <i>Journal of Autoimmunity</i> , 2014 , 53, 55-66 | 15.5 | 27 |
| 157 | OC-030 Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study. <i>Gut</i> , 2014 , 63, A15-A16 | 19.2 | |

| | | | |
|-----|---|------|-----|
| 156 | Genetics and epigenetics of primary biliary cirrhosis. <i>Seminars in Liver Disease</i> , 2014 , 34, 255-64 | 7.3 | 35 |
| 155 | Interpretation and perception of slow, moderate, and fast swimming paces in distance and sprint swimmers. <i>Perceptual and Motor Skills</i> , 2014 , 118, 833-49 | 2.2 | 5 |
| 154 | Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. <i>Gastroenterology</i> , 2014 , 147, 1338-49.e5; quiz e15 | 13.3 | 265 |
| 153 | Nuclear Envelope Protein Autoantibodies/Antilamin Autoantibodies 2014 , 219-223 | | |
| 152 | Primary biliary cirrhosis. Foreword. <i>Seminars in Liver Disease</i> , 2014 , 34, 253-4 | 7.3 | 6 |
| 151 | Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. <i>Frontiers in Immunology</i> , 2014 , 5, 128 | 8.4 | 46 |
| 150 | Vitamin D in autoimmune liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013 , 37, 535-45 | 2.4 | 36 |
| 149 | Tracing environmental markers of autoimmunity: introducing the infectome. <i>Immunologic Research</i> , 2013 , 56, 220-40 | 4.3 | 28 |
| 148 | Apoptosis and innate immune system: novel players in the primary biliary cirrhosis scenario. <i>Digestive and Liver Disease</i> , 2013 , 45, 630-6 | 3.3 | 17 |
| 147 | Intrahepatic cholestasis of pregnancy: a further important step in dissecting its genetic architecture. <i>Digestive and Liver Disease</i> , 2013 , 45, 266-7 | 3.3 | 5 |
| 146 | Infectome: a platform to trace infectious triggers of autoimmunity. <i>Autoimmunity Reviews</i> , 2013 , 12, 726-40 | 13.6 | 77 |
| 145 | Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. <i>Journal of Autoimmunity</i> , 2013 , 46, 1-6 | 15.5 | 37 |
| 144 | The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013 , 46, 81-7 | 15.5 | 52 |
| 143 | Y chromosome loss in male patients with primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013 , 41, 87-91 | 15.5 | 73 |
| 142 | Methylation and liver cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013 , 37, 564-71 | 2.4 | 14 |
| 141 | Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF- β receptor type II mouse. <i>Journal of Autoimmunity</i> , 2013 , 41, 111-9 | 15.5 | 85 |
| 140 | Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013 , 45, 670-5 | 36.3 | 267 |
| 139 | Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. <i>Genes and Immunity</i> , 2013 , 14, 179-86 | 4.4 | 44 |

| | | | |
|-----|--|------|-----|
| 138 | Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2013 , 173, 250-8 | 6.2 | 94 |
| 137 | MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. <i>Autoimmunity Reviews</i> , 2012 , 11, 305-14 | 13.6 | 133 |
| 136 | Autoimmunity and Turner's syndrome. <i>Autoimmunity Reviews</i> , 2012 , 11, A538-43 | 13.6 | 55 |
| 135 | Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2012 , 55, 153-60 | 11.2 | 93 |
| 134 | Iron levels in polarized macrophages: regulation of immunity and autoimmunity. <i>Autoimmunity Reviews</i> , 2012 , 11, 883-9 | 13.6 | 86 |
| 133 | Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. <i>Autoimmunity Reviews</i> , 2012 , 12, 300-4 | 13.6 | 61 |
| 132 | Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. <i>Autoimmunity Highlights</i> , 2012 , 3, 1-9 | 3.7 | 7 |
| 131 | The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. <i>Autoimmunity Highlights</i> , 2012 , 3, 127-32 | 3.7 | 2 |
| 130 | Towards common denominators in primary biliary cirrhosis: the role of IL-12. <i>Journal of Hepatology</i> , 2012 , 56, 731-3 | 13.4 | 35 |
| 129 | Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. <i>Journal of Hepatology</i> , 2012 , 57, 813-20 | 13.4 | 68 |
| 128 | Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. <i>Journal of Autoimmunity</i> , 2012 , 38, J193-6 | 15.5 | 47 |
| 127 | The X chromosome and immune associated genes. <i>Journal of Autoimmunity</i> , 2012 , 38, J187-92 | 15.5 | 199 |
| 126 | Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. <i>BMC Gastroenterology</i> , 2012 , 12, 92 | 3 | 23 |
| 125 | Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. <i>Hepatology</i> , 2012 , 55, 1495-506 | 11.2 | 24 |
| 124 | Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. <i>Clinical Reviews in Allergy and Immunology</i> , 2012 , 42, 288-97 | 12.3 | 50 |
| 123 | ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012 , 21, 5209-21 | 5.6 | 122 |
| 122 | Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. <i>Molecular and Cellular Proteomics</i> , 2012 , 11, 1885-97 | 7.6 | 28 |
| 121 | Sex differences associated with primary biliary cirrhosis. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 610504 | | 25 |

| | | | |
|-----|---|------|-----|
| 120 | Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. <i>Gut</i> , 2012 , 61, 268-77 | 19.2 | 93 |
| 119 | Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. <i>Genes and Immunity</i> , 2012 , 13, 461-8 | 4.4 | 66 |
| 118 | Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. <i>Digestive and Liver Disease</i> , 2011 , 43, 60-5 | 3.3 | 35 |
| 117 | Primary sclerosing cholangitis is changing clinical spectrum and old biomarkers disclose an innovative role: the case of alkaline phosphatase. <i>Digestive and Liver Disease</i> , 2011 , 43, 268-9 | 3.3 | 1 |
| 116 | Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. <i>Tissue Antigens</i> , 2011 , 77, 239-43 | | 20 |
| 115 | Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. <i>Tissue Antigens</i> , 2011 , 78, 65-8 | | 28 |
| 114 | Immunopathogenesis of primary biliary cirrhosis: an old wivesPtale. <i>Immunity and Ageing</i> , 2011 , 8, 12 | 9.7 | 22 |
| 113 | Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. <i>Hepatology</i> , 2011 , 54, 196-203 | 11.2 | 48 |
| 112 | Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving. <i>Hepatology</i> , 2011 , 54, 714-23 | 11.2 | 67 |
| 111 | Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. <i>Epigenetics</i> , 2011 , 6, 95-102 | 5.7 | 64 |
| 110 | Progress in the genetics of primary biliary cirrhosis. <i>Seminars in Liver Disease</i> , 2011 , 31, 147-56 | 7.3 | 57 |
| 109 | PtB as if PBC didnR existPt the illness experience of women affected by primary biliary cirrhosis. <i>Psychology and Health</i> , 2011 , 26, 1429-45 | 2.9 | 14 |
| 108 | Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. <i>American Journal of Physiology - Renal Physiology</i> , 2011 , 301, G623-33 | 5.1 | 41 |
| 107 | Hunting for fibrosis progression genes in hepatitis C patients. <i>Clinical Science</i> , 2011 , 120, 285-6 | 6.5 | |
| 106 | Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. <i>American Journal of Physiology - Cell Physiology</i> , 2011 , 300, C1078-89 | 5.4 | 19 |
| 105 | Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010 , 42, 658-60 | 36.3 | 337 |
| 104 | Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. <i>Cellular and Molecular Immunology</i> , 2010 , 7, 1-10 | 15.4 | 42 |
| 103 | A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis. <i>Digestive and Liver Disease</i> , 2010 , 42, 718-23 | 3.3 | 20 |

| | | | |
|-----|---|------|-----|
| 102 | Update on primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2010 , 42, 401-8 | 3.3 | 54 |
| 101 | Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. <i>Journal of Hepatology</i> , 2010 , 52, 712-7 | 13.4 | 40 |
| 100 | A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010 , 34, 55-8 | 15.5 | 80 |
| 99 | Geoepidemiology of autoimmune liver diseases. <i>Journal of Autoimmunity</i> , 2010 , 34, J300-6 | 15.5 | 69 |
| 98 | Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010 , 35, 176-80 | 15.5 | 58 |
| 97 | PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010 , 35, 436-42 | 15.5 | 103 |
| 96 | Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. <i>International Journal of Cancer</i> , 2010 , 126, 2112-22 | 7.5 | 34 |
| 95 | Definition of human autoimmunity--autoantibodies versus autoimmune disease. <i>Autoimmunity Reviews</i> , 2010 , 9, A259-66 | 13.6 | 171 |
| 94 | Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. <i>Hepatology</i> , 2010 , 52, 987-98 | 11.2 | 154 |
| 93 | Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in tauro lithocholic acid-induced cholestasis in rat liver. <i>Hepatology</i> , 2010 , 52, 1758-68 | 11.2 | 32 |
| 92 | Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. <i>BMC Gastroenterology</i> , 2010 , 10, 100 | 3 | 58 |
| 91 | Immune-mediated bile duct injury: The case of primary biliary cirrhosis. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2010 , 1, 118-28 | 3.2 | 3 |
| 90 | TNF-alpha polymorphisms in primary biliary cirrhosis: a northern and southern Italian experience. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 557-63 | 6.5 | 11 |
| 89 | Effect of L-acetylcarnitine on body composition in HIV-related lipodystrophy. <i>Hormone and Metabolic Research</i> , 2009 , 41, 840-5 | 3.1 | 19 |
| 88 | Apotopes and the biliary specificity of primary biliary cirrhosis. <i>Hepatology</i> , 2009 , 49, 871-9 | 11.2 | 158 |
| 87 | Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. <i>Hepatology</i> , 2009 , 50, 546-54 | 11.2 | 38 |
| 86 | Future directions in genetic for autoimmune diseases. <i>Journal of Autoimmunity</i> , 2009 , 33, 1-2 | 15.5 | 44 |
| 85 | Female predominance and X chromosome defects in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2009 , 33, 12-6 | 15.5 | 132 |

| | | | |
|----|---|------|------|
| 84 | The genetics of human autoimmune disease. <i>Journal of Autoimmunity</i> , 2009 , 33, 290-9 | 15.5 | 68 |
| 83 | Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. <i>Journal of Hepatology</i> , 2009 , 50, 1202-9 | 13.4 | 71 |
| 82 | EASL Clinical Practice Guidelines: management of cholestatic liver diseases. <i>Journal of Hepatology</i> , 2009 , 51, 237-67 | 13.4 | 1234 |
| 81 | Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. <i>Digestive and Liver Disease</i> , 2009 , 41, e8-e10 | 3.3 | 30 |
| 80 | Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. <i>Digestive and Liver Disease</i> , 2009 , 41, 523-33 | 3.3 | 12 |
| 79 | Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis. <i>Acta Hepatologica Japonica</i> , 2009 , 50, 51-59 | 0.3 | 1 |
| 78 | The genetic basis of primary biliary cirrhosis: premises, not promises. <i>Gastroenterology</i> , 2008 , 135, 1044-7 | 13.3 | 19 |
| 77 | Skewing of X chromosome inactivation in autoimmunity. <i>Autoimmunity</i> , 2008 , 41, 272-7 | 3 | 39 |
| 76 | New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. <i>Journal of Autoimmunity</i> , 2008 , 30, 84-9 | 15.5 | 194 |
| 75 | The consequences of apoptosis in autoimmunity. <i>Journal of Autoimmunity</i> , 2008 , 31, 257-62 | 15.5 | 98 |
| 74 | Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. <i>Autoimmunity</i> , 2008 , 41, 92-9 | 3 | 12 |
| 73 | Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. <i>Cancer Research</i> , 2008 , 68, 9184-93 | 10.1 | 75 |
| 72 | Serum autoantibodies: a road map for the clinical hepatologist. <i>Autoimmunity</i> , 2008 , 41, 27-34 | 3 | 16 |
| 71 | X chromosome in autoimmune diseases. <i>Expert Review of Clinical Immunology</i> , 2008 , 4, 591-7 | 5.1 | 4 |
| 70 | Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen. <i>Journal of Cellular Biochemistry</i> , 2008 , 104, 27-37 | 4.7 | 10 |
| 69 | Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. <i>Hepatology</i> , 2008 , 48, 1906-12 | 11.2 | 98 |
| 68 | Clinical features and management of primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , 2008 , 14, 3313-27 | 5.6 | 31 |
| 67 | Etiopathogenesis of primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , 2008 , 14, 3328-37 | 5.6 | 72 |

| | | | |
|----|--|------|-----|
| 66 | Autoimmune liver serology: current diagnostic and clinical challenges. <i>World Journal of Gastroenterology</i> , 2008 , 14, 3374-87 | 5.6 | 151 |
| 65 | A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. <i>Hepatology</i> , 2007 , 45, 659-65 | 11.2 | 129 |
| 64 | Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. <i>Hepatology</i> , 2007 , 46, 456-62 | 11.2 | 108 |
| 63 | Quality of life and everyday activities in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2007 , 46, 1836-43 | 6.1 | 24 |
| 62 | Role of X chromosome defects in primary biliary cirrhosis. <i>Hepatology Research</i> , 2007 , 37 Suppl 3, S384-85 | 1 | 4 |
| 61 | Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1109, 519-30 | 6.5 | 20 |
| 60 | The X chromosome in female-predominant autoimmune diseases. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1110, 57-64 | 6.5 | 27 |
| 59 | X monosomy in female systemic lupus erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1110, 84-91 | 6.5 | 45 |
| 58 | Bovine fetal microchimerism in normal and embryo transfer pregnancies and its implications for biotechnology applications in cattle. <i>Biotechnology Journal</i> , 2007 , 2, 486-91 | 5.6 | 23 |
| 57 | Fetal microchimerism in normal and embryo transfer bovine pregnancies. <i>Veterinary Research Communications</i> , 2007 , 31 Suppl 1, 205-7 | 2.9 | 10 |
| 56 | WHAT IS AN AUTOANTIBODY? 2007 , 3-6 | | 1 |
| 55 | Interpreting serological tests in diagnosing autoimmune liver diseases. <i>Seminars in Liver Disease</i> , 2007 , 27, 161-72 | 7.3 | 87 |
| 54 | Cytokines in Liver Health and Disease 2007 , 83-93 | | 1 |
| 53 | NUCLEAR ENVELOPE PROTEIN AUTOANTIBODIES/ANTILAMIN AUTOANTIBODIES 2007 , 191-196 | | 1 |
| 52 | Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. <i>Annals of Internal Medicine</i> , 2007 , 147, 451-9 | 8 | 45 |
| 51 | Autophagy: highlighting a novel player in the autoimmunity scenario. <i>Journal of Autoimmunity</i> , 2007 , 29, 61-8 | 15.5 | 83 |
| 50 | ANTINUCLEAR ANTIBODIES: GENERAL INTRODUCTION 2007 , 129-133 | | 1 |
| 49 | ANTIMITOCHONDRIAL ANTIBODIES 2007 , 473-477 | | 1 |

| | | | |
|----|--|------|-----|
| 48 | Primary Biliary Cirrhosis and Autoimmune Cholangitis 2007 , 235-247 | | 1 |
| 47 | Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. <i>Hepatology</i> , 2006 , 43, 1135-44 | 11.2 | 148 |
| 46 | Autoantibody Recognition of Functional Sites 2006 , 473-491 | | |
| 45 | The X chromosome and systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2006 , 18, 601-5 | 5.3 | 21 |
| 44 | From bases to basis: linking genetics to causation in primary biliary cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 401-10 | 6.9 | 72 |
| 43 | Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2005 , 24, 347-52 | 15.5 | 62 |
| 42 | Primary biliary cirrhosis: solving the enigma. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1051, 185-93 | 6.5 | 8 |
| 41 | Soluble CD40L in plasma of patients with primary biliary cirrhosis. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1051, 205-10 | 6.5 | 3 |
| 40 | Decreased serum leptin levels in primary biliary cirrhosis: a link between metabolism and autoimmunity?. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1051, 211-7 | 6.5 | 5 |
| 39 | The enigma of primary biliary cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2005 , 28, 73-81 | 12.3 | 14 |
| 38 | Genes and (auto)immunity in primary biliary cirrhosis. <i>Genes and Immunity</i> , 2005 , 6, 543-56 | 4.4 | 35 |
| 37 | Genes and goals: an approach to microarray analysis in autoimmunity. <i>Autoimmunity Reviews</i> , 2005 , 4, 414-22 | 13.6 | 22 |
| 36 | Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2005 , 41, 55-63 | 11.2 | 37 |
| 35 | SNP analysis of genes implicated in T cell proliferation in primary biliary cirrhosis. <i>Clinical and Developmental Immunology</i> , 2005 , 12, 259-63 | | 29 |
| 34 | Lack of serum antibodies to membrane bound carbonic anhydrase IV in patients with primary biliary cirrhosis. <i>Gut</i> , 2005 , 54, 1665 | 19.2 | |
| 33 | Genetics and geoeidemiology of primary biliary cirrhosis: following the footprints to disease etiology. <i>Seminars in Liver Disease</i> , 2005 , 25, 265-80 | 7.3 | 85 |
| 32 | Antinuclear antibodies in primary biliary cirrhosis. <i>Seminars in Liver Disease</i> , 2005 , 25, 298-310 | 7.3 | 146 |
| 31 | X chromosome monosomy: a common mechanism for autoimmune diseases. <i>Journal of Immunology</i> , 2005 , 175, 575-8 | 5.3 | 157 |

| | | | |
|----|---|------|-----|
| 30 | Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. <i>World Journal of Gastroenterology</i> , 2005 , 11, 1122-30 | 5.6 | 20 |
| 29 | Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis and their relatives. <i>American Journal of Gastroenterology</i> , 2004 , 99, 2143-6 | 0.7 | 46 |
| 28 | Primary biliary cirrhosis: does X mark the spot?. <i>Autoimmunity Reviews</i> , 2004 , 3, 493-9 | 13.6 | 36 |
| 27 | Tamoxifen in treatment of primary biliary cirrhosis. <i>Hepatology</i> , 2004 , 39, 1175-6 | 11.2 | 19 |
| 26 | Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. <i>Gastroenterology</i> , 2004 , 127, 485-92 | 13.3 | 378 |
| 25 | Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. <i>Gastroenterology</i> , 2004 , 127, 493-501 | 13.3 | 101 |
| 24 | Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2004 , 41, 905-12 | 13.4 | 96 |
| 23 | 544 Prognostic value of autoantibodies against proteins of nuclear pore complexes (anti-NPCS) in early primary biliary cirrhosis (PBC). <i>Journal of Hepatology</i> , 2004 , 40, 159-160 | 13.4 | 21 |
| 22 | Frequency of monosomy X in women with primary biliary cirrhosis. <i>Lancet, The</i> , 2004 , 363, 533-5 | 40 | 221 |
| 21 | Epidemiology and pathogenesis of primary biliary cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2004 , 38, 264-71 | 3 | 49 |
| 20 | Effect of anti-carbonic anhydrase antibodies on carbonic anhydrases I and II. <i>Clinical Chemistry</i> , 2003 , 49, 1221-3 | 5.5 | 28 |
| 19 | Geographic clusters of primary biliary cirrhosis. <i>Clinical and Developmental Immunology</i> , 2003 , 10, 127-31 | | 45 |
| 18 | Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. <i>Hepatology</i> , 2003 , 38, 1250-7 | 11.2 | 228 |
| 17 | Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: association with disease severity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003 , 18, 1150-4 | | 13 |
| 16 | Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003 , 38, 401-6 | 13.4 | 69 |
| 15 | T-cell receptor polymorphism in primary biliary cirrhosis. <i>Annali Italiani Di Medicina Interna: Organo Ufficiale Della Societ Italiana Di Medicina Interna</i> , 2003 , 18, 149-53 | | 2 |
| 14 | The search for a practical approach to emerging diseases: the case of severe acute respiratory syndrome (SARS). <i>Autoimmunity</i> , 2002 , 9, 113-7 | | 2 |
| 13 | Presence of fetal DNA in maternal plasma decades after pregnancy. <i>Human Genetics</i> , 2002 , 110, 587-91 | 6.3 | 56 |

| | | | |
|----|--|------|-----|
| 12 | Presence of fetal DNA in maternal plasma decades after pregnancy: further comments. <i>Human Genetics</i> , 2002 , 111, 576 | 6.3 | 6 |
| 11 | Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. <i>Gut</i> , 2002 , 51, 265-9 | 19.2 | 130 |
| 10 | Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 1427-34 | 6.1 | 32 |
| 9 | Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2001 , 34, 366-72 | 13.4 | 130 |
| 8 | Blood fetal microchimerism in primary biliary cirrhosis. <i>Clinical and Experimental Immunology</i> , 2000 , 122, 418-22 | 6.2 | 50 |
| 7 | Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. <i>Hepatology</i> , 1999 , 29, 320-7 | 11.2 | 67 |
| 6 | Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. <i>Clinical and Experimental Immunology</i> , 1998 , 114, 448-54 | 6.2 | 49 |
| 5 | Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. <i>Alimentary Pharmacology and Therapeutics</i> , 1997 , 11, 409-14 | 6.1 | 25 |
| 4 | Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. <i>Hepatology</i> , 1997 , 25, 1090-5 | 11.2 | 244 |
| 3 | Clinical pharmacokinetics of therapeutic bile acids. <i>Clinical Pharmacokinetics</i> , 1996 , 30, 333-58 | 6.2 | 67 |
| 2 | Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 809-15 | 4 | 38 |
| 1 | Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules | | 1 |